Monograph
J07CA06 - Diphtheria-Haemophilus Influenzae B-Pertussis-Poliomyelitis-Tetanus |
Propably not porphyrinogenic |
PNP |
Rationale
Based on the pharmacokinetics of the diphtheria-hemophilus influenzae B-pertussis-poliomyelitis-tetanus vaccine (DTP-IPV-Hib), there are no conceivable porphyrinogenic effects.
Chemical description
Diphtheria Toxoid, Tetanus Toxoid, Pertussis Toxoid, inactivated poliovirus (type 1,2 and 3) and Haemophilus influenzae Type b Polysaccharide (DTP-IPV-Hib)
Therapeutic characteristics
The DTP-IPV-Hib vaccine is indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type B disease from the age of 2 months. It is administered by intramuscular injections according to a three or four dose schedule.
Metabolism and pharmacokinetics
The DTP-IPV-Hib vaccine is not metabolized by the cytochrome P450 system.
References
| # | Citation details | PMID |
|---|---|---|
| * | Government bodies | |
| 1. | Norwegian Institute of Public Health. Vaksinasjonsveilederen. www.fhi.no (updated 13.10.2015).
|
|
| * | Summary of Product Characteristics | |
| 2. | The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). INFANRIX-IPV+Hib. (Last edition: 19.02. 2015).
|
|
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Belgium
United Kingdom
Denmark
Poland
Luxembourg
Iceland
Finland
Latvia
Serbia© NAPOS 2024